China
浙江恒驭生物科技有限公司 (Hengyu Biotechnology) is a biotech startup founded in 2020 in China. The company is committed to providing comprehensive services and products for biologic testing, process validation, and development for global pharmaceutical innovation enterprises. Hengyu Biotechnology utilizes BSL-2 level laboratories across China, complying with ISO9001, CNAS, and GLP requirements. Its comprehensive range of biologic testing projects covers the entire process from process development to market entry, ensuring the highest level of testing services with rigorous validation, detailed analysis, agile cycles, systematic management, and data confidentiality.
The last CNY200.00M Series B investment received by Hengyu Biotechnology on 11 March 2024 attracted a group of notable investors, including China Merchants Bank International, GP Capital, Jiashan Listed Cultivation Fund, Hangzhou Heda Industry Fund, CS Capital, Hongcheng Investment, and Mr. Zheng Xiaodong.
Hengyu Biotechnology aims to become a leading innovator in biologic drug testing, eliminating barriers for pharmaceutical enterprises in their innovation journey.
